


Healthcare News Roundup: Biopharmaceutical
HSMN NewsFeed - 12 Aug 2019
Daiichi Sankyo, Inc. Appoints Simon King as Chief People Officer across U.S. Divisions
Daiichi Sankyo, Inc. Appoints Simon King as Chief People Officer across U.S. Divisions
HSMN NewsFeed - 12 Aug 2019
CASI Pharmaceuticals Announces Launch of EVOMELA(R) (melphalan for injection) in China
CASI Pharmaceuticals Announces Launch of EVOMELA(R) (melphalan for injection) in China
HSMN NewsFeed - 29 Jul 2019
Epygenix Therapeutics Receives IND Approval of EPX-100 for the Treatment of Dravet Syndrome
Epygenix Therapeutics Receives IND Approval of EPX-100 for the Treatment of Dravet Syndrome
HSMN NewsFeed - 25 Jul 2019
Obsidian Therapeutics Announces Strengthening of Executive Leadership Team
Obsidian Therapeutics Announces Strengthening of Executive Leadership Team
HSMN NewsFeed - 25 Jul 2019
U.S. FDA Accepts Correvio's Resubmitted New Drug Application For Brinavess (vernakalant)
U.S. FDA Accepts Correvio's Resubmitted New Drug Application For Brinavess (vernakalant)
HSMN NewsFeed - 22 Jul 2019
Vanda Pharmaceuticals FDA Update for HETLIOZ(R) in the Treatment of Jet Lag Disorder
Vanda Pharmaceuticals FDA Update for HETLIOZ(R) in the Treatment of Jet Lag Disorder
HSMN NewsFeed - 19 Jul 2019
Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501
Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501
HSMN NewsFeed - 15 Jul 2019
AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma
AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma
HSMN NewsFeed - 15 Jul 2019
ESSA Expands Leadership Team by appointing Alessandra Cesano as Chief Medical Officer
ESSA Expands Leadership Team by appointing Alessandra Cesano as Chief Medical Officer
HSMN NewsFeed - 15 Jul 2019
Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder
Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder
HSMN NewsFeed - 12 Jul 2019
Lilly's OVERCOME Observational Study Reveals Inconsistent and Sub-Optimal Treatment Landscape for Migraine
Lilly's OVERCOME Observational Study Reveals Inconsistent and Sub-Optimal Treatment Landscape for Migraine
HSMN NewsFeed - 8 Jul 2019
Skyhawk Therapeutics Announces Expansion of Collaboration Agreement with Biogen
Skyhawk Therapeutics Announces Expansion of Collaboration Agreement with Biogen
HSMN NewsFeed - 8 Jul 2019
Skyhawk Therapeutics Announces Addition of World Leading SAB Head & New VP of Oncology Biology
Skyhawk Therapeutics Announces Addition of World Leading SAB Head & New VP of Oncology Biology
HSMN NewsFeed - 8 Jul 2019
Soligenix Announces Appointment of Diane L. Parks to its Board of Directors
Soligenix Announces Appointment of Diane L. Parks to its Board of Directors
HSMN NewsFeed - 3 Jul 2019
Caris Life Sciences Appoints Steven D. Averbuch, M.D., to Its Scientific Advisory Board
Caris Life Sciences Appoints Steven D. Averbuch, M.D., to Its Scientific Advisory Board
HSMN NewsFeed - 1 Jul 2019
Squarex Appoints Biopharmaceutical Industry Veteran Jack V. Talley as Chief Executive Officer
Squarex Appoints Biopharmaceutical Industry Veteran Jack V. Talley as Chief Executive Officer
HSMN NewsFeed - 28 Jun 2019
Lannett Enters Into Distribution Agreement For Dantrolene Capsules, Commences Product Launch
Lannett Enters Into Distribution Agreement For Dantrolene Capsules, Commences Product Launch
HSMN NewsFeed - 28 Jun 2019
Amgen and UCB Provide Regulatory Update on Status of EVENITY(TM) (romosozumab) in the EU
Amgen and UCB Provide Regulatory Update on Status of EVENITY(TM) (romosozumab) in the EU
HSMN NewsFeed - 27 Jun 2019
DURECT Announces Submission to FDA of a Full Response to the POSIMIR(R) Complete Response Letter
DURECT Announces Submission to FDA of a Full Response to the POSIMIR(R) Complete Response Letter
HSMN NewsFeed - 26 Jun 2019
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
HSMN NewsFeed - 25 Jun 2019
SmartPharm Therapeutics Appoints José Trevejo, MD, PhD, as Chief Executive Officer
SmartPharm Therapeutics Appoints José Trevejo, MD, PhD, as Chief Executive Officer
HSMN NewsFeed - 24 Jun 2019
BioEclipse Therapeutics(TM) Announces Appointment of New Directors and Series A-1 Financing
BioEclipse Therapeutics(TM) Announces Appointment of New Directors and Series A-1 Financing
HSMN NewsFeed - 21 Jun 2019
FDA Approves BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity
FDA Approves BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity
HSMN NewsFeed - 20 Jun 2019
OxThera Initiates Extension Part of a Phase 3 Study of Oxabact in Primary Hyperoxaluria
OxThera Initiates Extension Part of a Phase 3 Study of Oxabact in Primary Hyperoxaluria
HSMN NewsFeed - 19 Jun 2019
HemoShear Therapeutics Names Biopharma Veteran Kathleen M. Metters, PhD, to Board of Directors
HemoShear Therapeutics Names Biopharma Veteran Kathleen M. Metters, PhD, to Board of Directors
HSMN NewsFeed - 19 Jun 2019
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the U.S. FDA
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the U.S. FDA
